Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of
population and according to the World Health Organization (WHO) the number of adults …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1),
glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have …